Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA)

Abdalrhman, Ihab; Gurt, Irina; Katz, Ehud

doi:10.1016/j.vaccine.2006.02.012

Cited by 23 publications

(28 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mice were euthanized 30 days p.i. and blood samples were collected for neutralization tests (NT); these were carried out using purified VACV-WR intracellular mature virus (Abdalrhman et al, 2006). Animal experimentation was carried out in accordance with regulations and guidelines of Ethical and Animal Use Committee of Universidade Federal de Minas Gerais, Brazil.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Vaccinia virus: shedding and horizontal transmission in a murine model

Ferreira

Abrahão

Drumond

et al. 2008

Journal of General Virology

View full text Add to dashboard Cite

Vaccinia virus (VACV) has been associated with several bovine vaccinia outbreaks in Brazil, affecting cattle and humans. There are no available data about VACV environmental circulation or the role of wildlife in the emergence of an outbreak. Since VACV was isolated from rodents in Brazil, we investigated shedding and transmission of VACV strains in mice. The VACV excretion profile was assessed by PCR and chicken chorioallantoic membrane infection, revealing viral DNA and infectious virus in the faeces and urine of intranasally infected mice. Horizontal transmission was assessed by exposure of sentinel mice to wood shavings contaminated with excrement, to mimic a natural infection. Sentinel mice showed orthopoxvirus antibodies, and VACV DNA and infectious virus were detected in their faeces and intestines, even after six rounds of natural transmission. Together, these data suggest that murine excrement could play a relevant role in VACV spread and transmission, perhaps helping to explain how these viruses circulate between their natural hosts.

show abstract

mentioning

confidence: 99%

“…All rounds of transmission followed the same protocol described above. All uninfected mice were previously tested by NT to confirm OPV seronegativity (Abdalrhman et al, 2006). Faecal samples from sentinel mice were collected for 10 days p.e.…”

mentioning

confidence: 99%

Vaccinia virus: shedding and horizontal transmission in a murine model

Ferreira

Abrahão

Drumond

et al. 2008

Journal of General Virology

View full text Add to dashboard Cite

show abstract

“…Moreover, the immunogenicity of MVA is thought to be equivalent to that of conventional smallpox vaccines (13,21,27). MVA also displays reduced virulence in animals (1,31,37), and clinical trials in West Germany in the 1970s demonstrated it has an excellent safety profile in humans (19). MVA is therefore considered more suitable for immunocompromised individuals, children, or those with skin conditions such as atopic dermatitis, for whom conventional vaccines are contraindicated.…”

mentioning

confidence: 99%

Antibody Profiling by Proteome Microarray Reveals the Immunogenicity of the Attenuated Smallpox Vaccine Modified Vaccinia Virus Ankara Is Comparable to That of Dryvax

Davies

Wyatt

Newman

et al. 2008

J Virol

117

127

View full text Add to dashboard Cite

Modified vaccinia virus Ankara (MVA) is a highly attenuated vaccinia virus that is under consideration as an alternative to the conventional smallpox vaccine Dryvax. MVA was attenuated by extensive passage of vaccinia virus Ankara in chicken embryo fibroblasts. Several immunomodulatory genes and genes that influence host range are deleted or mutated, and replication is aborted in the late stage of infection in most nonavian cells. The effect of these mutations on immunogenicity is not well understood. Since the structural genes appear to be intact in MVA, it is hypothesized that critical targets for antibody neutralization have been retained. To test this, we probed microarrays of the Western Reserve (WR) proteome with sera from humans and macaques after MVA and Dryvax vaccination. As most protein sequences of MVA are 97 to 99% identical to those of other vaccinia virus strains, extensive binding cross-reactivity is expected, except for those deleted or truncated. Despite different hosts and immunization regimens, the MVA and Dryvax antibody profiles were broadly similar, with antibodies against membrane and core proteins being the best conserved. The responses to nonstructural proteins were less well conserved, although these are not expected to influence virus neutralization. The broadest antibody response was obtained for hyperimmune rabbits with WR, which is pathogenic in rabbits. These data indicate that, despite the mutations and deletions in MVA, its overall immunogenicity is broadly comparable to that of Dryvax, particularly at the level of antibodies to membrane proteins. The work supports other information suggesting that MVA may be a useful alternative to Dryvax.

show abstract

“…We characterized the virus population comprising the Lister stock, used in Israel for many years for vaccination against smallpox. This stock was found to be heterogeneous and contained a mixture of viruses, forming plaques of different diameter in tissue cultures [13]. Three variants of the Lister stock were isolated and plaque purified: large plaque (LP), middle plaque (MP) and small plaque (SP); their different diameter in the plaque assay is clearly visible [13].…”

Section: Introductionmentioning

confidence: 99%

“…This stock was found to be heterogeneous and contained a mixture of viruses, forming plaques of different diameter in tissue cultures [13]. Three variants of the Lister stock were isolated and plaque purified: large plaque (LP), middle plaque (MP) and small plaque (SP); their different diameter in the plaque assay is clearly visible [13]. Furthermore, initial studies which we performed showed that Previously we found that C-terminal truncation of 35 amino acids in the A33R envelope protein of vaccinia virus causes enhanced release of extracellular virions from infected cells at the completion of the growth cycle of the virus, and also to significant attenuation of the virus for mice [14].…”

Section: Introductionmentioning

confidence: 99%

Pathogenicity for Mice of a Recombinant of Vaccinia Virus and Protection Against Infection with a Lethal Virus

Gurt¹,

Katz

2011

TOANTIMJ

View full text Add to dashboard Cite

Abstract:The population of the stock of the Lister strain of vaccinia virus, applied in Israel for immunization against smallpox, was found to be heterogeneous. A middle-size plaque (MP) virus was found to be the most attenuated for mice, out of the three variants which we characterized. Previously we found that C-terminal truncation of the A33R viral envelope protein of vaccinia virus leads to an enhanced release of free virus from the infected cells and to attenuation of the virus for mice. A recombinant of the MP variant with such truncation, was now constructed and found to release more progeny virus from the infected cells and slightly more attenuated for mice than its parent virus. This new recombinant of vaccinia virus may be useful when vaccination against smallpox would be required again, in the future.

show abstract

Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA)

Cited by 23 publications

References 19 publications

Vaccinia virus: shedding and horizontal transmission in a murine model

Vaccinia virus: shedding and horizontal transmission in a murine model

Antibody Profiling by Proteome Microarray Reveals the Immunogenicity of the Attenuated Smallpox Vaccine Modified Vaccinia Virus Ankara Is Comparable to That of Dryvax

Pathogenicity for Mice of a Recombinant of Vaccinia Virus and Protection Against Infection with a Lethal Virus

Contact Info

Product

Resources

About